Research map: Increasing formulary adoption of adalimumab biosimilars and differential cost-sharing in Medicare Part D plans

Back to the article

Papers in this map

  1. The Effect of Health Insurance on Prescription Drug Use Among Low-Income Adults:Evidence from Recent Medicaid Expansions · Ausmita Ghosh · 2018 · 120 citations · Cited by this paper
  2. Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years · 2026 · Related
  3. A Systematic Literature Review Assessing the Directional Impact of Managed Care Formulary Restrictions on Medication Adherence, Clinical Outcomes, Economic Outcomes, and Health Care Resource Utilization · Laura E. Happe · 2014 · 69 citations · Cited by this paper
  4. Comparative efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF) and concentrated growth factors (CGF) for female pattern hair loss (FPHL): a prospective multicenter randomized clinical trial · 2026 · Related
  5. Clinical and Regulatory Concerns of Biosimilars: A Review of Literature · Vesa Halimi · 2020 · 61 citations · Cited by this paper
  6. Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial · 2026 · Related
  7. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review · C. Rieger · 2024 · 28 citations · Cited by this paper
  8. Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study · 2026 · Related
  9. Obstacles to Biosimilar Acceptance and Uptake in Oncology · Daniel K. Mroczek · 2024 · 14 citations · Cited by this paper
  10. Effect of methotrexate on endothelial function in psoriasis patients · 2026 · Related
  11. Uptake of oncology-related biosimilars: a global analysis of usage data · Martin K. H. Ho · 2025 · 2 citations · Cited by this paper
  12. Evaluation of the clinical applicability of artificial intelligence in determining systemic therapy indications and treatment selection in psoriasis · 2026 · Related
  13. Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States · Joseph F. Levy · 2026 · 1 citation · Cited by this paper
  14. Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials · 2026 · Related
  15. Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment · 2026 · Related
  16. Recalcitrant tinea infections due to Trichophyton indotineae in the United States (2025–2026): a retrospective case series identified by real-time PCR · 2026 · Related
  17. Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study · 2026 · Related

Source: OpenAlex (CC0)